-
平臺編號：bio-68243
-
國際編號：CRL-2725?
-
細(xì)胞信息： Kasumi-3
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
Kasumi-3
生長狀態(tài)：懸浮生長
器官來源：外周血
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：原始粒細(xì)胞
細(xì)胞類型：淋巴母細(xì)胞
ATCC Number：CRL-2725?
相關(guān)疾病：其他疾病
是否是腫瘤細(xì)胞：0
物種來源：人
數(shù)量：大量
年限：57 years adult
規(guī)格：0.2ml Designations: Kasumi-3
Depositors: ?H Asou
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens deposited as human
Morphology:myeloblast
Source: Organ: peripheral blood
Disease: acute myeloblastic leukemia
Cell Type: lymphoblast
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Mie, Japan
Isolation date: July 18, 1990
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 11
D13S317: 11,12
D16S539: 9,11
D5S818: 12
D7S820: 10,11
THO1: 6,9
TPOX: 8
vWA: 16,18
Cytogenetic Analysis:t(3:7) (q27;q22), del(5)(q15), del(9)(q32), add(12)(p11)
Age: 57 years adult
Gender: male
Ethnicity: Japanese
Comments:The cell line was established from the blast cells of a myeloperoxidase-negative acute leukemia patient. The cell line expresses CD7, CD4, CD13, CD33, CD34, HLA-DR and c-Kit on cell surface compatible with that of acute myelocytic leukemia, subtype M0 (AML-M0). Kasumi-3 has t(3;7)(q27:q22), del(5)(q15), del(9)(q32), and add(12)(p11) chromosomal abnormalities. The breakpoint of 3q27 is located near the EVI1 gene. A high level of expression of the EVI1 gene was observed. Kasumi-3 cells treated with TPA showed maturation to monocytic lineage. Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 X 10(5) viable cells/ml.
Interval: Maintain cell density between 3 X 10(5) and 3 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 45 to 60 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
Bioreactive Factors: Differentiation Inducers: 12-O-tetradecanoylphorbol-13-acetate (TPA)
References: 57590: Asou H, et al. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn. J. Cancer Res. 87: 269-274, 1996. PubMed: 8613429
61297: Mochizuki N, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96: 3209-3214, 2000. PubMed: 11050005
61298: Suzukawa K, et al. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics 42: 356-360, 1997. PubMed: 9192861
61299: Suzukawa K, et al. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia 13: 1359-1366, 1999. PubMed: 10482986
器官來源：外周血
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：原始粒細(xì)胞
細(xì)胞類型：淋巴母細(xì)胞
ATCC Number：CRL-2725?
相關(guān)疾病：其他疾病
是否是腫瘤細(xì)胞：0
物種來源：人
數(shù)量：大量
年限：57 years adult
規(guī)格：0.2ml Designations: Kasumi-3
Depositors: ?H Asou
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens deposited as human
Morphology:myeloblast
Source: Organ: peripheral blood
Disease: acute myeloblastic leukemia
Cell Type: lymphoblast
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Mie, Japan
Isolation date: July 18, 1990
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 11
D13S317: 11,12
D16S539: 9,11
D5S818: 12
D7S820: 10,11
THO1: 6,9
TPOX: 8
vWA: 16,18
Cytogenetic Analysis:t(3:7) (q27;q22), del(5)(q15), del(9)(q32), add(12)(p11)
Age: 57 years adult
Gender: male
Ethnicity: Japanese
Comments:The cell line was established from the blast cells of a myeloperoxidase-negative acute leukemia patient. The cell line expresses CD7, CD4, CD13, CD33, CD34, HLA-DR and c-Kit on cell surface compatible with that of acute myelocytic leukemia, subtype M0 (AML-M0). Kasumi-3 has t(3;7)(q27:q22), del(5)(q15), del(9)(q32), and add(12)(p11) chromosomal abnormalities. The breakpoint of 3q27 is located near the EVI1 gene. A high level of expression of the EVI1 gene was observed. Kasumi-3 cells treated with TPA showed maturation to monocytic lineage. Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 X 10(5) viable cells/ml.
Interval: Maintain cell density between 3 X 10(5) and 3 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 45 to 60 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
Bioreactive Factors: Differentiation Inducers: 12-O-tetradecanoylphorbol-13-acetate (TPA)
References: 57590: Asou H, et al. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn. J. Cancer Res. 87: 269-274, 1996. PubMed: 8613429
61297: Mochizuki N, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96: 3209-3214, 2000. PubMed: 11050005
61298: Suzukawa K, et al. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics 42: 356-360, 1997. PubMed: 9192861
61299: Suzukawa K, et al. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia 13: 1359-1366, 1999. PubMed: 10482986
